Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-17
2008-12-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S253000
Reexamination Certificate
active
07470694
ABSTRACT:
Pyrimidone compounds of formula (I):are inhibitors of the enzyme Lp-PLA2and are of use in treating atheroscelerosis.
REFERENCES:
patent: 6649619 (2003-11-01), Hickey et al.
patent: 7153861 (2006-12-01), Leach et al.
patent: WO 99/24420 (1999-05-01), None
patent: WO 00/66567 (2000-11-01), None
Hickey, et al. Chemical Abstracts, vol. 135 entry 195570, 2001.
Lerman, Women and Ischemia Syndrome Evaluation (WISE) Diagnosis and Pathophysiology of Ischemic Heart Disease Workshop. Oct. 2002.
Koren, Diastolic Congestive Hearl Failure, Jacksonville Medicine. Feb. 2002.
Iribarren et at., Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Calcified Coronary Plaque in Young Adults, Arterioscler Thromb Vasc Biol., 25:216-221, Jan. 2005.
I McAllister et al., Randomised trials of secondary prevention programmes in coronary heart disease: systematic review, BMJ, vol. 323, pp. 957-962, Oct. 2001.
Leach Colin Andrew
Smith Stephen Allan
Stanway Steven James
Kanagy James M.
Kinzig Charles M.
Rao Deepak
SmithKline Beecham PLC
Venetianer Stephen
LandOfFree
5,6-trimethylenepyrimidin-4-one compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5,6-trimethylenepyrimidin-4-one compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5,6-trimethylenepyrimidin-4-one compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050216